CN117529311A - 治疗和预防病毒感染相关的神经系统并发症的新的化合物 - Google Patents
治疗和预防病毒感染相关的神经系统并发症的新的化合物 Download PDFInfo
- Publication number
- CN117529311A CN117529311A CN202280043349.6A CN202280043349A CN117529311A CN 117529311 A CN117529311 A CN 117529311A CN 202280043349 A CN202280043349 A CN 202280043349A CN 117529311 A CN117529311 A CN 117529311A
- Authority
- CN
- China
- Prior art keywords
- compound
- day
- metabolite
- pharmaceutical composition
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
- C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
- C07C69/30—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with trihydroxylic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
- A61K36/12—Filicopsida or Pteridopsida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21180462.0 | 2021-06-18 | ||
| EP21180462 | 2021-06-18 | ||
| PCT/EP2022/066548 WO2022263624A1 (en) | 2021-06-18 | 2022-06-17 | Novel compounds for the treatment and prevention of neurological complications of viral infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117529311A true CN117529311A (zh) | 2024-02-06 |
Family
ID=76532115
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280043349.6A Pending CN117529311A (zh) | 2021-06-18 | 2022-06-17 | 治疗和预防病毒感染相关的神经系统并发症的新的化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240307339A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4355316A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024523429A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240022560A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117529311A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022263624A1 (cg-RX-API-DMAC7.html) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4150125A (en) * | 1977-09-30 | 1979-04-17 | Abbott Laboratories | Triglyceride ester of phosphonoacetic acid having antiviral activity |
| CN102781438A (zh) * | 2009-12-30 | 2012-11-14 | 贝勒研究院 | 用于阿尔茨海默病和脑衰老的补给疗法 |
| CN104940589A (zh) * | 2015-06-18 | 2015-09-30 | 王峰 | 治疗急性结膜炎的中药制剂及制法 |
| CN110300581A (zh) * | 2016-06-08 | 2019-10-01 | 善睿圣医药保健股份有限公司 | 具有奇数碳的脂类化合物及其作为医药组合物或者营养补充剂的用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000007581A (ja) * | 1998-06-18 | 2000-01-11 | Nippon Kayaku Co Ltd | 抗ウイルススプレー剤 |
| WO2018159941A1 (ko) * | 2017-03-02 | 2018-09-07 | 대화제약 주식회사 | 자나미비르를 포함하는 안정한 약제학적 조성물 |
| KR101991661B1 (ko) * | 2017-03-02 | 2019-06-21 | 대화제약 주식회사 | 자나미비르를 포함하는 안정한 약제학적 조성물 |
| WO2019052629A1 (en) * | 2017-09-12 | 2019-03-21 | Sunregen Healthcare Ag | LIPIDS HAVING AN IMPERATIVE NUMBER OF CARBON ATOMS AND THEIR USE AS A PHARMACEUTICAL COMPOSITION OR FOOD SUPPLEMENT |
-
2022
- 2022-06-17 JP JP2023578116A patent/JP2024523429A/ja active Pending
- 2022-06-17 KR KR1020247001041A patent/KR20240022560A/ko active Pending
- 2022-06-17 EP EP22734578.2A patent/EP4355316A1/en active Pending
- 2022-06-17 US US18/571,123 patent/US20240307339A1/en active Pending
- 2022-06-17 WO PCT/EP2022/066548 patent/WO2022263624A1/en not_active Ceased
- 2022-06-17 CN CN202280043349.6A patent/CN117529311A/zh active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4150125A (en) * | 1977-09-30 | 1979-04-17 | Abbott Laboratories | Triglyceride ester of phosphonoacetic acid having antiviral activity |
| CN102781438A (zh) * | 2009-12-30 | 2012-11-14 | 贝勒研究院 | 用于阿尔茨海默病和脑衰老的补给疗法 |
| CN104940589A (zh) * | 2015-06-18 | 2015-09-30 | 王峰 | 治疗急性结膜炎的中药制剂及制法 |
| CN110300581A (zh) * | 2016-06-08 | 2019-10-01 | 善睿圣医药保健股份有限公司 | 具有奇数碳的脂类化合物及其作为医药组合物或者营养补充剂的用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022263624A1 (en) | 2022-12-22 |
| KR20240022560A (ko) | 2024-02-20 |
| US20240307339A1 (en) | 2024-09-19 |
| JP2024523429A (ja) | 2024-06-28 |
| EP4355316A1 (en) | 2024-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yu et al. | Akebia saponin D attenuates ibotenic acid-induced cognitive deficits and pro-apoptotic response in rats: involvement of MAPK signal pathway | |
| US12594255B2 (en) | Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement | |
| ES2459540T3 (es) | Composiciones que comprenden extractos de andrographis paniculata combinados con extractos de ginkgo biloba en complejos con fosfolípidos, y su uso. | |
| Kiyofuji et al. | A natural compound macelignan protects midbrain dopaminergic neurons from inflammatory degeneration via microglial arginase-1 expression | |
| US20230078820A1 (en) | Fenfluramine for treatment of demyelinating diseases and conditions | |
| Kang et al. | Roots of Lithospermum erythrorhizon promotes retinal cell survival in optic nerve crush-induced retinal degeneration | |
| Asuku et al. | Coffee and Parkinson's disease | |
| Ma et al. | Beneficial effects of cornel iridoid glycoside on behavioral impairment and senescence status in SAMP8 mice at different ages | |
| CN103933058A (zh) | 木犀草素-7-二葡萄糖醛酸苷在制备治疗视网膜退行性病变药物中的应用 | |
| US20210317455A1 (en) | Inhibitor of tdp-43 aggregation | |
| US20200093929A1 (en) | Pharmaceutical composition for the prevention and treatment of memory and cognitive deficits related to ageing | |
| JP5783377B2 (ja) | 網膜色素変性症を予防する及び遅発させるためのセリンパルミトイルトランスフェラーゼ阻害剤 | |
| KR101807953B1 (ko) | 고수 추출물을 유효성분으로 하는 치매 예방 또는 치료용 약학적 조성물 | |
| US10588911B2 (en) | Compositions comprising triterpenoids | |
| TW202033212A (zh) | 沉香萃取物之用途 | |
| AU2021204964A1 (en) | Composition for use in the treatment of cognitive disorders | |
| US20240307339A1 (en) | Novel compounds for the treatment and prevention of neurological complications of viral infections | |
| KR102538278B1 (ko) | 진토닌을 유효성분으로 포함하는 헌팅턴병 예방 또는 치료용 조성물 | |
| JP5714524B2 (ja) | 痴呆の予防および治療におけるL−n−ブチルフタリドの適用 | |
| HK40021759B (en) | Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement | |
| KR20210130991A (ko) | 헤르바세틴을 유효성분으로 포함하는 뇌전증지속증 또는 신경퇴행 예방 또는 치료용 조성물 | |
| EP4429647A1 (en) | Compositions for the management of demyelinating disorders | |
| HK40021759A (en) | Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |